Prescription Drug User Fee Act (PDUFA) Target Action Date of
Approval of BLA would unlock a
Nine-month year over year reduction in costs and operating expenses of approximately 83%
“The resubmission of the tab-cel BLA was an important milestone this quarter, and we remain focused on supporting
Tabelecleucel (tab-cel® or EBVALLO™) for Post-Transplant Lymphoproliferative Disease (PTLD)
As previously communicated, the
The BLA has a Class 2 Resubmission Prescription Drug User Fee Act (PDUFA) target action date of
If tabelecleucel is approved by the
Third Quarter 2026 Financial Results:
- Cash, cash equivalents and short-term investments as of
September 30, 2026 , totaled$9.9 million , as compared to$9.9 million as ofJune 30, 2026 . - Net cash used in operating activities was
$0.9 million for the third quarter 2026, as compared to$9.8 million in the same period in 2025. - Total revenues were
$1.2 million for the third quarter 2026, as compared to$3.5 million for the same period in 2025. Total revenues decreased by$2.3 million year-over-year, primarily due to the one-time sale of clinical inventory in the prior year. - Total costs and operating expenses include non-cash stock-based compensation, depreciation and amortization expenses of
$0.5 million for the third quarter 2026, as compared to$1.3 million for the same period in 2025. - Research and development expenses were
$1.1 million for the third quarter 2026, as compared to$2.9 million for the same period in 2025. - Research and development expenses include
$0.1 million of non-cash stock-based compensation expenses for the third quarter 2026, as compared to$0.3 million for the same period in 2025. - General and administrative expenses were
$2.8 million for the third quarter 2026, as compared to$4.0 million for the same period in 2025. - General and administrative expenses include
$0.4 million of non-cash stock-based compensation expenses for the third quarter 2026, as compared to$0.9 million for the same period in 2025. - Atara reported a net loss of
$2.2 million , or ($0.15 ) basic and diluted loss per share, for the third quarter 2026, as compared to net loss of$4.3 million , or ($0.32 ) basic and diluted loss per share, for the same period in 2025.
2026 Outlook and Cash Runway:
- Operating expenses are expected to decline significantly year-over-year, reflecting the full-year benefit of cost-reduction initiatives implemented in 2025 and the first half of 2026.
- Atara expects its cash, cash equivalents, and short-term investments as of
September 30, 2026 , combined with operating efficiencies achieved in 2025 and the first half of 2026, will be sufficient to fund planned operations into mid-2027.
About
Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases. Atara is headquartered in
Forward-Looking Statements
This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding: (1) the development, timing and progress of tab-cel, including the FDA’s review of the resubmitted tab-cel BLA and the PDUFA target action date, the potential characteristics and benefits of tab-cel, and the results of, and prospects for bringing tab-cel to
Condensed Consolidated Balance Sheets (Unaudited) (In thousands, except per share amounts) | ||||||||
|
|
|
|
|
|
| ||
|
| |||||||
|
| 2026 |
| 2025 | ||||
Assets |
|
|
|
|
|
| ||
Current assets: |
|
|
|
|
|
| ||
Cash and cash equivalents |
| $ | 4,055 |
|
| $ | 8,482 |
|
Short-term investments |
|
| 5,862 |
|
|
| — |
|
Accounts receivable |
|
| 691 |
|
|
| 1,253 |
|
Other current assets |
|
| 705 |
|
|
| 2,477 |
|
Total current assets |
|
| 11,313 |
|
|
| 12,212 |
|
Property and equipment, net |
|
| 38 |
|
|
| 73 |
|
Operating lease assets |
|
| 6,494 |
|
|
| 7,064 |
|
Other assets |
|
| 762 |
|
|
| 886 |
|
Total assets |
| $ | 18,607 |
|
| $ | 20,235 |
|
|
|
|
|
|
|
| ||
Liabilities and stockholders’ equity (deficit) |
|
|
|
|
|
| ||
Current liabilities: |
|
|
|
|
|
| ||
Accounts payable |
| $ | 762 |
|
| $ | 127 |
|
Accrued compensation |
|
| 471 |
|
|
| 1,271 |
|
Accrued research and development expenses |
|
| 24 |
|
|
| 82 |
|
Deferred revenue |
|
| 513 |
|
|
| 716 |
|
Liability related to the sale of future revenues – current portion |
|
| 1,105 |
|
|
| 9,750 |
|
Other current liabilities |
|
| 3,693 |
|
|
| 2,976 |
|
Total current liabilities |
|
| 6,568 |
|
|
| 14,922 |
|
Operating lease liabilities – long-term |
|
| 8,482 |
|
|
| 9,347 |
|
Liability related to the sale of future revenues – long-term |
|
| 39,560 |
|
|
| 32,673 |
|
Other long-term liabilities |
|
| 1,899 |
|
|
| 1,795 |
|
Total liabilities |
|
| 56,509 |
|
|
| 58,737 |
|
|
|
|
|
|
|
| ||
Commitments and contingencies |
|
|
|
|
|
| ||
|
|
|
|
|
|
| ||
Stockholders’ equity (deficit): |
|
|
|
|
|
| ||
Common stock—$0.0001 par value, 500,000 shares authorized as of |
|
| 1 |
|
|
| 1 |
|
Additional paid-in capital |
|
| 1,995,171 |
|
|
| 1,983,361 |
|
Accumulated other comprehensive income (loss) |
|
| (1 | ) |
|
| 1 |
|
Accumulated deficit |
|
| (2,033,073 | ) |
|
| (2,021,865 | ) |
Total stockholders’ equity (deficit) |
|
| (37,902 | ) |
|
| (38,502 | ) |
Total liabilities and stockholders’ equity (deficit) |
| $ | 18,607 |
|
| $ | 20,235 |
|
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) (In thousands, except per share amounts) | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
| Three Months Ended |
| Nine Months Ended | ||||||||||||
|
| 2026 |
| 2025 |
| 2026 |
| 2025 | ||||||||
Commercialization revenue |
| $ | 1,224 |
|
| $ | 3,453 |
|
| $ | 2,370 |
|
| $ | 119,177 |
|
Costs and operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Cost of commercialization revenue |
|
| 265 |
|
|
| 115 |
|
|
| 580 |
|
|
| 21,108 |
|
Research and development expenses |
|
| 1,099 |
|
|
| 2,925 |
|
|
| 2,608 |
|
|
| 37,668 |
|
General and administrative expenses |
|
| 2,830 |
|
|
| 3,987 |
|
|
| 10,241 |
|
|
| 21,976 |
|
Total costs and operating expenses |
|
| 4,194 |
|
|
| 7,027 |
|
|
| 13,429 |
|
|
| 80,752 |
|
Income (loss) from operations |
|
| (2,970 | ) |
|
| (3,574 | ) |
|
| (11,059 | ) |
|
| 38,425 |
|
Other income (expense), net: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Interest income |
|
| 68 |
|
|
| 204 |
|
|
| 199 |
|
|
| 583 |
|
Interest income (expense) on sale of future revenues |
|
| 682 |
|
|
| (906 | ) |
|
| (333 | ) |
|
| (2,745 | ) |
Other income (expense), net |
|
| (9 | ) |
|
| 1 |
|
|
| (14 | ) |
|
| (138 | ) |
Total other income (expense), net |
|
| 741 |
|
|
| (701 | ) |
|
| (148 | ) |
|
| (2,300 | ) |
Income (loss) before provision for (benefit from) income taxes |
|
| (2,229 | ) |
|
| (4,275 | ) |
|
| (11,207 | ) |
|
| 36,125 |
|
Provision for (benefit from) income taxes |
|
| — |
|
|
| 28 |
|
|
| 1 |
|
|
| 31 |
|
Net income (loss) |
| $ | (2,229 | ) |
| $ | (4,303 | ) |
| $ | (11,208 | ) |
| $ | 36,094 |
|
Other comprehensive gain (loss): |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Unrealized gain (loss) on available-for-sale securities |
|
| 1 |
|
|
| 2 |
|
|
| (2 | ) |
|
| (6 | ) |
Comprehensive income (loss) |
| $ | (2,228 | ) |
| $ | (4,301 | ) |
| $ | (11,210 | ) |
| $ | 36,088 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Basic (loss) earnings per common share |
| $ | (0.15 | ) |
| $ | (0.32 | ) |
| $ | (0.76 | ) |
| $ | 2.96 |
|
Diluted (loss) earnings per common share |
| $ | (0.15 | ) |
| $ | (0.32 | ) |
| $ | (0.76 | ) |
| $ | 2.93 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Basic and diluted weighted-average shares outstanding |
|
| 15,326 |
|
|
| 13,564 |
|
|
| 14,818 |
|
|
| 12,185 |
|
Diluted weighted-average shares outstanding |
|
| 15,326 |
|
|
| 13,564 |
|
|
| 14,818 |
|
|
| 12,319 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20261110294532/en/
Investor and Media Relations
Sr. Director, Strategy and Operations
adaugherty@atarabio.com
Source: